ASPI — Q2 2026 Financial Report Analysis

Overview

ASP Isotopes' second quarter of 2026 (three months to June 30) looks far better than a year ago at first glance: the net loss attributable to shareholders shrank to $33.6 million from $75.1 million, and revenue more than quadrupled to $5.1 million. Both comparisons flatter the quarter. Last year's loss was swollen by a $63.8 million non-cash charge from revaluing convertible notes, and this year's revenue jump comes mostly from businesses the company bought: US radiopharmacies (East Coast Nuclear Pharmacy in October 2025, Numed in January 2026) and South African gas producer Renergen (January 2026). The core plan, selling enriched isotopes from its Pretoria plants, has still not produced a dollar of revenue. Strip out the note revaluations and the underlying loss widened to $30.1 million from $11.2 million, as operating costs nearly tripled.

At a glance

• $5.1 million revenue (+328% YoY): $3.9 million from nuclear-medicine doses for PET and SPECT scans, $0.7 million from Renergen's LNG and $0.6 million of TerraPower collaboration revenue. None of it is from enriched isotopes yet.
• $35.7 million operating expenses (up from $12.5 million): overheads (SG&A) rose $17.2 million, more than a third of that from professional fees tied to deals. Spending is roughly seven times revenue.
• $254.9 million cash and short-term investments at June 30, down from $327.3 million at December 31, with $41.1 million burned by operations in the first half. The company says this lasts more than 12 months.

Results summary

Operating margin (operating loss divided by revenue) is shown for completeness but means little at this revenue scale; percentage changes in a loss are marked "n/m" (not meaningful). Headline loss is the company's own non-GAAP figure, which it publishes because of its secondary listing on the Johannesburg Stock Exchange.

Where the revenue came from

The company now reports three segments:

• Radiopharmacies. Dose sales for PET and SPECT medical scans were $3.9 million against $1.2 million. The 10-Q attributes $1.1 million of the rise in cost of revenue to the ECNP and Numed acquisitions but does not split out their revenue, so how much of the growth is from existing sites cannot be calculated from the filing.
• Renergen. LNG sales were $0.7 million for the quarter ($1.2 million since the January 6 acquisition). Liquid helium, the product the deal was mainly about, is not yet being sold; management ties it to completing Phase 1 of the Virginia Gas Project.
• TerraPower. $0.6 million of collaboration revenue (milestone payments) from the US nuclear developer, which is lined up as the customer for QLE's planned high-assay low-enriched uranium (HALEU, a more concentrated reactor fuel).
• Sequentially, revenue rose to $5.1 million from $4.2 million in Q1 2026 (first-half revenue $9.3 million less Q2).

Gross margin fell to 28.9% from 47.7%. The mix moved toward newly acquired radiopharmacies and an LNG plant that is still ramping, and cost of revenue includes $0.7 million of depletion (the gas-field equivalent of depreciation) on Renergen's natural gas properties.

Costs: why the loss widened underneath

• Selling, general and administrative rose to $28.9 million from $11.7 million. The largest pieces of the $17.2 million increase in the MD&A are $6.5 million more professional fees ("primarily due to corporate development activity" and the Renergen and ECNP acquisitions), $5.7 million more personnel costs, $2.3 million more facility and depreciation costs and $1.8 million of travel and other costs. SG&A also rose from $21.3 million in Q1, so the second quarter was more expensive than the first.
• Research and development rose to $6.8 million from $0.9 million: $2.2 million more personnel, $1.4 million of contract services and consulting "in order to optimize commercial production," $0.9 million of exploration costs at Renergen and $0.6 million of manufacturing engineering for pre-commercial operations.

A good part of the SG&A rise is deal work: buying Renergen, preparing to list QLE separately, and the June 25 agreement to put Renergen into Nasdaq-listed ENDRA Life Sciences (to be renamed Noble Africa). Some of that should fade once those transactions close. The personnel and facility costs belong to a larger company and are unlikely to.

What the headline numbers hide

• The "narrower loss" is an accounting comparison, not an improvement. Q2 2025 carried a $63.8 million loss from marking QLE's convertible notes to fair value (they rise in value as the share price rises); Q2 2026 carried only $3.5 million. Excluding those revaluations, the loss rose 170% to $30.1 million. The operating loss, which no revaluation affects, rose to $34.2 million from $12.0 million.
• Other one-offs both ways. The quarter got a $2.6 million foreign-exchange gain and $2.7 million of interest income on the cash pile, offset by $1.8 million of interest expense, most of it on Renergen's debt. Below the quarter, the first-half figures include $19.6 million of income from discontinued operations: the gain from deconsolidating Skyline Builders, a Hong Kong construction company that QLE stopped controlling on March 29. That boost sits in Q1, not Q2.
• Per-share figures are flattered by dilution. Weighted shares rose 68% to 122.7 million, from three stock offerings in 2025 and 14.27 million shares issued for Renergen. After the quarter, on July 16, holders of about $109.2 million of QLE notes swapped them for roughly 23.2 million ASPI shares, so the share count rose again in Q3.
• Cash burn is rising. Operating cash outflow was $41.1 million in the first half against $11.1 million a year earlier. Capital spending was $10.2 million, plus $14.1 million put into stakes in biotech companies Opeongo and ENDRA. Part of the $72.4 million fall in cash and short-term investments since December is Skyline's $50.7 million of cash leaving the books on deconsolidation, which was never ASPI's to spend.
• Renergen's debt is in breach. About $53 million of Renergen's loans sit in current liabilities: the $22.8 million DFC facility (in default on reporting and security-registration covenants), the $8.5 million IDC loan (financial covenants breached since February 15), the $13.7 million Standard Bank loan (past its March 31, 2026 maturity, with an extension to August 2027 still being negotiated) and $8.3 million of debentures held by AIRSOL that are in a legal dispute. Management says it expects waivers and amendments; none is signed in the filing.
• Internal controls are not effective. Management again concluded its disclosure controls were not effective because of the material weaknesses reported in the 2025 annual report, which itself had to be amended.
• Receivables grew faster than sales: accounts receivable rose to $3.0 million from $1.1 million at year-end, mostly from consolidating acquired businesses. It is small in dollars.

Takeaway: Take out the swings in the value of QLE's convertible notes and ASP Isotopes lost $30.1 million this quarter, almost three times the $11.2 million of a year ago, on $5.1 million of revenue from businesses it mostly bought. The investment case still rests on enriched-isotope sales that have not started. The second half of 2026 is when management has said they would.

Outlook

• First isotope shipments. The 10-Q repeats targets of initial commercial shipments of enriched carbon-14 (used to label drug and agrochemical molecules), silicon-28 (for semiconductors and quantum computing) and ytterbium-176 (feedstock for a cancer radiotherapy isotope) in the second half of 2026, with carbon-14 dependent "on the timing and the quality of the feedstock received from our customer." Shipments by December would be the first proof the enrichment technology can earn money.
• Helium. At its September 8 Capital Markets Day, management said it expects liquid helium production as Phase 1 of the Virginia Gas Project is completed, and growth in radiopharmacy revenue, over the next 12 months. It also set a target of more than $300 million of EBITDA in 2031. EBITDA is earnings before interest, tax, depreciation and amortization. Phase 2 of Virginia is estimated to cost about $1.16 billion; DFC and Standard Bank have indicated they may lend up to $500 million and $250 million, but nothing is committed.
• Corporate structure. The Renergen/ENDRA merger is expected to close in Q4 2026 (deadline December 24), with ASPI owning about 89% of Noble Africa, and a separate QLE listing is still planned. Both would move most of the capital needs of the gas and uranium businesses into their own listed vehicles.

Our read: Revenue will keep rising as acquisitions consolidate and LNG and helium ramp up, but costs are rising faster, and the company has funded itself with equity and convertible notes, which has meant steady dilution. The things to watch in Q3 (period ending September 30): whether the first isotope revenue shows up or slips into 2027; whether SG&A falls back from $28.9 million once deal fees stop; and whether Renergen's lenders sign the waivers and the Standard Bank extension. With about $255 million of liquid funds and roughly $20 million a quarter of operating burn, cash is not the near-term risk. The open question is whether isotope revenue and margins arrive before the next equity raise.

This is the first ASP Isotopes report published on this site, so there is no earlier outlook to check against.